Nevada Accuses Juul of Targeting Youth in Lawsuit

Dec.08.2022
Nevada Accuses Juul of Targeting Youth in Lawsuit
Juul accused of marketing to minors and deceiving consumers on nicotine content in Nevada civil suit.

The Nevada Attorney General's office has accused electronic cigarette manufacturer Juul of following the playbook of "big tobacco companies," attempting to make their products attractive to minors and deceiving consumers about the nicotine content in their devices.


In a civil lawsuit filed on Tuesday, the state claimed that Juul Labs, Inc. of San Francisco has hindered the state government's efforts to ban the sale of most flavored cigarettes and market products to people under the age of 21, which was implemented by Congress in the 1990s and later.


State officials said in the lawsuit, "Thanks to the joint efforts of states, the federal government, public health advocates, and many others, the smoking rates among youth and adults have decreased significantly. Unfortunately, the emergence of e-cigarettes has reversed much of the progress.


The complaint was filed after Nevada had reached an agreement with Juul Labs in September, as one of 32 states to settle with the company for $438 million. Nevada's portion of the settlement amounted to $14.4 million. Juul also agreed to stop advertising its electronic cigarettes to minors and to cease using sponsorships and social media influencers to promote its products.


An appeal has been filed with the Clark County District Court in Las Vegas, requesting a permanent injunction to prevent Juul Labs from engaging in violations of Nevada's Deceptive Trade Practices Act. The appeal also calls for civil penalties to be imposed for each infraction committed by the company and urges consideration for compensation and refunds.


A spokesperson for Juul, Arik Ben-Zvi, said that Nevada's application does not constitute a new complaint against the company, but is related to a multi-state settlement agreement reached in September, which includes Nevada.


He stated, "The terms of the agreement align with our current business practices that were established since the company-wide restructuring in autumn 2019.


The US Food and Drug Administration banned the sale of Juul products in June, but suspended its decision after Juul appealed, awaiting a review of further "scientific" issues.


In a complaint filed this week, officials in Nevada compared the e-cigarette industry to the "big tobacco" companies of the pre-1990s, when companies "realized that increasing cigarette sales depended to a large extent on getting individuals addicted to their products from a young age.


As a result, major tobacco companies have developed a comprehensive plan to attract vulnerable children and entice them to use their products,” the office stated. “They have also spent significant resources to expose young people to tobacco imagery through magazine ads, sporting events, and billboards.


Juul Labs sells electronic cigarettes using its proprietary product called a "pod," which delivers nicotine to the users inhaling the e-cigarette.


The pods of the company contain significantly more nicotine compared to other brands and include "nicotine salts" pioneered by Juul Labs, making the inhalant smoother and less irritating than earlier types of electronic smoking devices, according to national officials.


The Office of the Attorney General stated that the company, in its marketing efforts, misled consumers into believing that its products were either nicotine-free or had a lower nicotine concentration and were a safer alternative to combustible cigarettes.


According to state officials, Juul Labs has been selling its tobacco devices to minors from the beginning and, in fact, "the main driver of its explosive growth is young people adopting its products.


A complaint alleges that the company has focused marketing efforts on Instagram, Twitter, Facebook and other social media channels to target younger users.


2FIRSTS will continue to follow and report on this topic. Further updates will be available on the "2FIRSTS APP". Scan the QR code below to download the app.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

2Firsts Hosts China Market Forum at InterTabac as Global Industry Attention to China’s Tobacco Sector Deepens
2Firsts Hosts China Market Forum at InterTabac as Global Industry Attention to China’s Tobacco Sector Deepens
On September 16, 2Firsts hosted a China-focused industry forum during InterTabac in Dortmund, bringing together more than 30 participants from North America, Europe, India, South Korea and other markets. The session covered traditional tobacco, next-generation products, exports, technology, regulation and supply chains, while examining how China’s tobacco sector operates, where its transformation may be heading, and why its growing role matters increasingly to companies across the global tobacco and nicotine industry.
Sep.21
Charlie’s Bets on Age-Gating and 678 PMTA Assets as U.S. Vape Enforcement Landscape Shifts
Charlie’s Bets on Age-Gating and 678 PMTA Assets as U.S. Vape Enforcement Landscape Shifts
Charlie’s Holdings said in its latest shareholder letter that it is moving to commercialize PACHA products and monetize its PMTA assets as the FDA changes enforcement priorities for unauthorized ENDS products. Thirty PACHA SKUs were previously tentatively identified for a proposed public list of products that the FDA generally does not intend to prioritize for enforcement. Charlie’s is also preparing test-market sales of age-gated flavored disposables and says it currently holds 678 PMTA-related product assets while seeking additional strategic transactions and partnerships.
Sep.11
PMI CEO Attends Opening of IQOS Global Flagship in Tokyo’s Ginza as 1,814 Limited ILUMA i PRIME Sets Launch
PMI CEO Attends Opening of IQOS Global Flagship in Tokyo’s Ginza as 1,814 Limited ILUMA i PRIME Sets Launch
IQOS opened its first global flagship, IQOS Flagship Ginza, in Tokyo on September 4, 2026, replacing the former IQOS Store Ginza after nearly a decade of operation. The new location expands conventional product retail into member lounges, digital experiences, art installations and brand programming. IQOS also launched a Ginza-exclusive IQOS ILUMA i PRIME set limited to 1,814 individually numbered units, priced at JPY11,980, or about US$77. PMI Sales Strategy Consultant Yuji M. later said on LinkedIn that more than 500 people had lined up from the night before the opening.
Sep.07
U.S. Judge Stays Helix, NJOY Challenge to FDA PMTA Rule Pending New Rulemaking Court Stays Altria's Helix, NJOY Challenge to PMTA Rule as FDA Prepares New Rulemaking
U.S. Judge Stays Helix, NJOY Challenge to FDA PMTA Rule Pending New Rulemaking Court Stays Altria's Helix, NJOY Challenge to PMTA Rule as FDA Prepares New Rulemaking
A federal judge in Texas on Oct. 8 granted a joint request by the FDA and plaintiffs including Altria subsidiaries Helix Innovations and NJOY to stay litigation challenging the agency's 2021 PMTA rule. The court cited FDA's anticipated rulemaking concerning the regulation at issue. FDA announced on Sept. 28 that it intends to reassess the PMTA framework and could initiate new rulemaking to replace it. The parties must file a joint status report within 45 days and every 45 days thereafter. A motion by three Reynolds American companies to intervene remains pending.
Regulations
Oct.10
FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
Turning Point Brands said Executive Chairman David E. Glazek will become CEO on October 1, replacing Graham Purdy, who is stepping down for personal reasons. The company narrowed its 2026 adjusted EBITDA outlook to $70 million-$80 million from $70 million-$90 million while maintaining Modern Oral gross sales guidance of $330 million-$350 million and net sales guidance of $260 million-$270 million. In the second quarter, Modern Oral net sales rose 128% to $68.4 million and accounted for 48% of company-wide net sales. Adjusted EBITDA fell 50% year over year. TPB shares closed about 10% lower on September 21.
Market
Sep.22 by 2Firsts Perspectives
Ukraine Raises Excise Stamp Fees for Tobacco, Heated Tobacco and Vape Liquids by 30.5% as Parliament Backs E-Excise Delay to 2027
Ukraine Raises Excise Stamp Fees for Tobacco, Heated Tobacco and Vape Liquids by 30.5% as Parliament Backs E-Excise Delay to 2027
Ukraine's Cabinet of Ministers adopted Resolution No. 1259 on October 15, 2026, increasing excise stamp production fees for tobacco products and e-cigarette liquids by approximately 30.5%, from UAH 0.1643 to UAH 0.2144 per stamp. Fees for alcoholic beverages rose by about 30.2%. Separately, Ukraine's parliament passed Bill No. 15532 on October 13, proposing to postpone the full implementation of electronic excise stamps and traceability for alcohol, tobacco and e-cigarette liquids from November 1, 2026, to July 1, 2027. Parliament cited additional testing, configuration and integration requirements. The bill was sent to the president for signature on October 19.
Regulations
Oct.21